

Ling Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9676597/publications.pdf>

Version: 2024-02-01

121
papers

2,545
citations

201385

27
h-index

264894

42
g-index

124
all docs

124
docs citations

124
times ranked

4138
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical analysis of patients with primary and secondary extranodal natural killer/Tâ€cell lymphoma of central nervous system. <i>Hematological Oncology</i> , 2023, 41, 267-274.	0.8	3
2	Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 42-50.	0.3	2
3	Generation of a human iPSC line ZZUNEUI014-A from a patient with antithrombin deficiency caused by mutation in SERPINC1 gene. <i>Stem Cell Research</i> , 2022, 59, 102646.	0.3	3
4	Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation. <i>Leukemia and Lymphoma</i> , 2022, , 1-6.	0.6	0
5	Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study. <i>Investigational New Drugs</i> , 2022, 40, 650-659.	1.2	19
6	Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Endocrinology</i> , 2022, 13, 846357.	1.5	5
7	Efficacy and Safety of a Pegasparginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma. <i>JAMA Oncology</i> , 2022, 8, 1035.	3.4	21
8	Linc00883 affects colorectal cancer through miR-577/FKBP14 axis: a novel mechanism for regulating colorectal cancer cell proliferation, invasion, and migration. <i>Cell Cycle</i> , 2022, 21, 2403-2416.	1.3	1
9	MYD88 L265P elicits mutation-specific ubiquitination to drive NF-ÎB activation and lymphomagenesis. <i>Blood</i> , 2021, 137, 1615-1627.	0.6	21
10	Radiotherapy vs sequential pegasparginase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/Tâ€cell lymphoma: A randomized, controlled, open-label, multicenter study. <i>International Journal of Cancer</i> , 2021, 148, 1470-1477.	2.3	10
11	DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/Tâ€cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients. <i>Clinical and Translational Science</i> , 2021, 14, 405-411.	1.5	8
12	Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial. <i>Cancer Biology and Medicine</i> , 2021, 19, 1089-1099.	1.4	1
13	Generation of an iPSC line from a patient with hypertrophic cardiomyopathy carrying a mutation in MYH6 gene. <i>Stem Cell Research</i> , 2021, 50, 102138.	0.3	1
14	Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2021, 100, 1509-1516.	0.8	11
15	A new surgical technique for post-myocardial infarction ventricular septal rupture with hemodynamic instability. <i>Chinese Medical Journal</i> , 2021, 134, 981-983.	0.9	3
16	Identification of Prognostic Related Genes of Tumor Microenvironment Derived From Esophageal Cancer Patients. <i>Pathology and Oncology Research</i> , 2021, 27, 589662.	0.9	3
17	Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure. <i>Frontiers in Oncology</i> , 2021, 11, 687374.	1.3	9
18	Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma. <i>Cancer Research and Treatment</i> , 2021, 53, 837-846.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Protection against Doxorubicin-Related Cardiotoxicity by Jaceosidin Involves the Sirt1 Signaling Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-18.	1.9	4
20	Clinical Characteristics and Contemporary Prognosis of Ventricular Septal Rupture Complicating Acute Myocardial Infarction: A Single-Center Experience. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 679148.	1.1	4
21	Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 686595.	1.8	3
22	Intervention Effect of Probiotics in Gastric Cancer Patients with Complications of Coronary Heart Disease and Heart Failure. <i>Journal of Oncology</i> , 2021, 2021, 1-6.	0.6	3
23	The Impact of the Immunophenotyping Characteristics of Patients' Peripheral Blood on the Manufacturing and Clinical Outcome of CD7-Targeted Chimeric Antigen Receptor T Cells. <i>Blood</i> , 2021, 138, 3830-3830.	0.6	3
24	Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase II Trial. <i>Blood</i> , 2021, 138, 1368-1368.	0.6	1
25	A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma. <i>Blood</i> , 2021, 138, 3829-3829.	0.6	13
26	Assessing the evidenceâ€“practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2020, 22, 646-660.	2.9	38
27	Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CT. <i>European Journal of Radiology</i> , 2020, 133, 109301.	1.2	9
28	<p>Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7189-7197.	1.0	13
29	Targeting PD-L1 in non-small cell lung cancer using CAR T cells. <i>Oncogenesis</i> , 2020, 9, 72.	2.1	48
30	Overexpression of Ubiquitin-Specific Protease 2 (USP2) in the Heart Suppressed Pressure Overload-Induced Cardiac Remodeling. <i>Mediators of Inflammation</i> , 2020, 2020, 1-12.	1.4	9
31	Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. <i>Investigational New Drugs</i> , 2020, 38, 1847-1853.	1.2	28
32	Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) <i>versus</i> CHOP in newly diagnosed peripheral T-cell lymphoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092382.	1.4	9
33	An integration-free iPSC line ZZLINEU008-A derived from dermal fibroblasts of a child with cardiac valvular dysplasia carrying a mutation in FLNA gene. <i>Stem Cell Research</i> , 2020, 47, 101882.	0.3	2
34	<p>Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 275-284.	2.0	6
35	Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma. <i>Haematologica</i> , 2020, 105, e107-e110.	1.7	7
36	First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3026-3026.	0.8	13

#	ARTICLE	IF	CITATIONS
37	A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma. <i>Immunotherapy</i> , 2020, 12, 681-696.	1.0	14
38	Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients. <i>Journal of Clinical Oncology</i> , 2020, 38, 8018-8018.	0.8	0
39	Fotemustine-Based in Combination with Rituximab As First-Line Induction Chemotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma: a Prospective Phase II Trial. <i>Blood</i> , 2020, 136, 5-5.	0.6	0
40	Prevalence of CYP17A1 gene mutations in 17 β -hydroxylase deficiency in the Chinese Han population. <i>Clinical Hypertension</i> , 2019, 25, 23.	0.7	12
41	Panax Notoginseng Saponins Protect Cardiac Myocytes Against Endoplasmic Reticulum Stress and Associated Apoptosis Through Mediation of Intracellular Calcium Homeostasis. <i>Frontiers in Pharmacology</i> , 2019, 10, 1013.	1.6	15
42	Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China. <i>Cancer Management and Research</i> , 2019, Volume 11, 8277-8284.	0.9	0
43	NLRP3 inflammasome mediate palmitate-induced endothelial dysfunction. <i>Life Sciences</i> , 2019, 239, 116882.	2.0	32
44	Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. <i>Nature Communications</i> , 2019, 10, 5061.	5.8	18
45	Prognostic nomogram for overall survival in upper aerodigestive tract extranodal natural killer/T cell lymphoma, nasal type, stages IE and IIE: A SEER-based study. <i>Oncology Letters</i> , 2019, 18, 3493-3500.	0.8	2
46	Dopamine D4 receptor protected against hyperglycemia-induced endothelial dysfunction via PI3K/eNOS pathway. <i>Biochemical and Biophysical Research Communications</i> , 2019, 518, 554-559.	1.0	8
47	Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2019, Volume 9, 33-43.	1.2	6
48	Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma. <i>Nature Communications</i> , 2019, 10, 4209.	5.8	25
49	Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells. <i>Cancer Medicine</i> , 2019, 8, 3892-3904.	1.3	23
50	Fabrication of superparamagnetic nano-silica@ quercetin-encapsulated PLGA nanocomposite: Potential application for cardiovascular diseases. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2019, 196, 111508.	1.7	28
51	Intensive versus Usual Control of Hypertension in the Prevention of Cardiovascular and Renal Outcomes: A Cumulative Meta-Analysis of Randomized Controlled Trials. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 384-395.	0.9	4
52	Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study. <i>Cancer Management and Research</i> , 2019, Volume 11, 1363-1372.	0.9	8
53	Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma. <i>Oncologist</i> , 2019, 24, e1123-e1131.	1.9	22
54	Clinical features and prognostic factors of primary bone marrow lymphoma. <i>Cancer Management and Research</i> , 2019, Volume 11, 2553-2563.	0.9	9

#	ARTICLE	IF	CITATIONS
55	Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signalâ€Regulating Kinase 1 Pathways. <i>Hepatology</i> , 2019, 70, 1099-1118.	3.6	42
56	The long noncoding RNA XIST regulates cardiac hypertrophy by targeting miRâ€101. <i>Journal of Cellular Physiology</i> , 2019, 234, 13680-13692.	2.0	55
57	Recurrent PDGFRB mutations in unicentric Castleman disease. <i>Leukemia</i> , 2019, 33, 1035-1038.	3.3	48
58	MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1. <i>Cancer Biology and Therapy</i> , 2019, 20, 31-41.	1.5	32
59	Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labelled Study with Ddgp Regimen Versus SMILE Regimen. <i>Blood</i> , 2019, 134, 463-463.	0.6	11
60	B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma. <i>Aging</i> , 2019, 11, 3939-3957.	1.4	6
61	TRPM7 channel inhibition exacerbates pulmonary arterial hypertension through MEK/ERK pathway. <i>Aging</i> , 2019, 11, 4050-4065.	1.4	20
62	Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured By 18F-FDG PET-CT in Patients with T-Cell Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 2851-2851.	0.6	0
63	Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study. <i>Blood</i> , 2019, 134, 2873-2873.	0.6	0
64	Progranulin ameliorates coxsackievirus-B3-induced viral myocarditis by downregulating Th1 and Th17 cells. <i>Experimental Cell Research</i> , 2018, 367, 241-250.	1.2	27
65	Penile metastasis secondary to nasal-type extranodal natural killer/T-cell lymphoma: A case report and review of the literature. <i>Oncology Letters</i> , 2018, 15, 8034-8038.	0.8	2
66	Therapeutic benefits of <sc>CD</sc>90â€negative cardiac stromal cells in rats with a 30â€day chronic infarct. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 1984-1991.	1.6	7
67	Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngsters. <i>Scientific Reports</i> , 2018, 8, 1088.	1.6	10
68	SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphoma. <i>Experimental Cell Research</i> , 2018, 364, 125-132.	1.2	14
69	Hyperoside Suppresses Lipopolysaccharide-induced Inflammation and Apoptosis in Human Umbilical Vein Endothelial Cells. <i>Current Medical Science</i> , 2018, 38, 222-228.	0.7	20
70	miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 58.	6.9	98
71	<i>MYD88</i> L265P Mutation in Lymphoid Malignancies. <i>Cancer Research</i> , 2018, 78, 2457-2462.	0.4	92
72	miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. <i>Oncogene</i> , 2018, 37, 3151-3165.	2.6	90

#	ARTICLE	IF	CITATIONS
73	Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma. <i>British Journal of Haematology</i> , 2018, 181, 406-410.	1.2	22
74	Analyses and treatment of simultaneous B-lineage malignancies of myeloid leukemia and lymphoma: Two case reports and a literature review. <i>Oncology Letters</i> , 2018, 16, 6624-6632.	0.8	8
75	Evaluation of Cardiovascular Risk Factors and Restless Legs Syndrome in Women and Men: A Preliminary Population-Based Study in China. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 445-450.	1.4	13
76	Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?. <i>Cancer Cell International</i> , 2018, 18, 150.	1.8	3
77	Saikosaponin A Protects From Pressure Overload-Induced Cardiac Fibrosis via Inhibiting Fibroblast Activation or Endothelial Cell EndMT. <i>International Journal of Biological Sciences</i> , 2018, 14, 1923-1934.	2.6	35
78	Clinicopathological analysis of the hydroa vacciniforme-like lymphoproliferative disorder with natural killer cell phenotype compared with cutaneous natural killer T-cell lymphoma. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 4772-4778.	0.8	1
79	AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma. <i>Molecular Medicine</i> , 2018, 24, 35.	1.9	18
80	ClqTNF-related protein 1 attenuates doxorubicin-induced cardiac injury via activation of AKT. <i>Life Sciences</i> , 2018, 207, 492-498.	2.0	21
81	Lymphoma associated hemophagocytic syndrome: A single-center retrospective study. <i>Oncology Letters</i> , 2018, 16, 1275-1284.	0.8	28
82	Melatonin improves cardiac function in a mouse model of heart failure with preserved ejection fraction. <i>Redox Biology</i> , 2018, 18, 211-221.	3.9	35
83	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 15.	6.9	155
84	Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. <i>Journal of Neuro-Oncology</i> , 2018, 140, 427-434.	1.4	22
85	An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Oncotarget</i> , 2018, 9, 16213-16219.	0.8	10
86	Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma. <i>Oncology Letters</i> , 2017, 13, 1211-1215.	0.8	12
87	Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells. <i>Scientific Reports</i> , 2017, 7, 682.	1.6	24
88	The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. <i>British Journal of Haematology</i> , 2017, 178, 772-780.	1.2	25
89	Kaempferol Alleviates Angiotensin II-Induced Cardiac Dysfunction and Interstitial Fibrosis in Mice. <i>Cellular Physiology and Biochemistry</i> , 2017, 43, 2253-2263.	1.1	37
90	Sanggenon C protects against pressure overload-induced cardiac hypertrophy via the calcineurin/NFAT2 pathway. <i>Molecular Medicine Reports</i> , 2017, 16, 5338-5346.	1.1	8

#	ARTICLE	IF	CITATIONS
91	Pretreatment 14â€³â€³ epsilon level is predictive for advanced extranodal NK/T cell lymphoma therapeutic response to asparaginaseâ€³based chemotherapy. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1600111.	0.8	10
92	NF-Î²B signaling pathway and its potential as a target for therapy in lymphoid neoplasms. <i>Blood Reviews</i> , 2017, 31, 77-92.	2.8	81
93	Concentration-dependent effects of paeoniflorin on proliferation and apoptosis of vascular smooth muscle cells. <i>Molecular Medicine Reports</i> , 2017, 16, 9567-9572.	1.1	8
94	Effects of microRNA-21 on the biological functions of T-cell acute lymphoblastic lymphoma/leukemia. <i>Oncology Letters</i> , 2016, 12, 4173-4180.	0.8	12
95	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 3083-3100.	0.6	59
96	DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China. <i>Clinical Cancer Research</i> , 2016, 22, 5223-5228.	3.2	112
97	Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 2177-2184.	0.8	9
98	microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer. <i>Oncology Reports</i> , 2016, 36, 3529-3535.	1.2	32
99	Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma. <i>Oncology Letters</i> , 2016, 11, 693-698.	0.8	13
100	Adipose tissue deficiency results in severe hyperlipidemia and atherosclerosis in the low-density lipoprotein receptor knockout mice. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 410-418.	1.2	20
101	Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque in Patients with Coronary Heart Disease. <i>Heart Lung and Circulation</i> , 2016, 25, 459-465.	0.2	38
102	Effects of vitamin D supplementation as an adjuvant therapy in coronary artery disease patients. <i>Scandinavian Cardiovascular Journal</i> , 2016, 50, 9-16.	0.4	25
103	Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. <i>Leukemia</i> , 2016, 30, 361-372.	3.3	55
104	Restless legs syndrome and pregnancy or delivery complications in China: a representative survey. <i>Sleep Medicine</i> , 2016, 17, 158-162.	0.8	31
105	RelA NF-Î²B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016, 8, 3321-3340.	1.4	29
106	Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149. <i>Oncotarget</i> , 2016, 7, 55721-55731.	0.8	19
107	MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 53808-53819.	0.8	21
108	GDPT Versus CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma: A Prospective Randomized Controlled, Open-Label Study (No.NCT01664975). <i>Blood</i> , 2016, 128, 2989-2989.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Alpinetin enhances cholesterol efflux and inhibits lipid accumulation in oxidized low-density lipoprotein-loaded human macrophages. <i>Biotechnology and Applied Biochemistry</i> , 2015, 62, 840-847.	1.4	16
110	Increased expression of LncRNA BANCR is associated with clinical progression and poor prognosis in gastric cancer. <i>Biomedicine and Pharmacotherapy</i> , 2015, 72, 109-112.	2.5	92
111	Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2613-2618.	0.6	12
112	ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target. <i>Leukemia Research</i> , 2015, 39, 1448-1454.	0.4	18
113	Prognostic impact of c-Rel nuclear expression and c-REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 23157-23180.	0.8	35
114	Prognostic value of total bilirubin in patients with angina pectoris undergoing percutaneous coronary intervention. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 15930-9.	1.3	6
115	Effect of small interference RNA on the acetylcholine-sensitive potassium channel in H9c2 cells. <i>Annals of Clinical and Laboratory Science</i> , 2015, 45, 58-63.	0.2	0
116	Red Blood Cell Distribution Width and Long-Term Outcome in Patients Undergoing Percutaneous Coronary Intervention in the Drug-Eluting Stenting Era: A Two-Year Cohort Study. <i>PLoS ONE</i> , 2014, 9, e94887.	1.1	29
117	Curcumin attenuates cardiac fibrosis in spontaneously hypertensive rats through PPAR- γ activation. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 1247-1256.	2.8	45
118	Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre. <i>BMJ Open</i> , 2014, 4, e004892-e004892.	0.8	23
119	HMGB1 Is Involved in the Protective Effect of the PPAR- α Agonist Fenofibrate against Cardiac Hypertrophy. <i>PPAR Research</i> , 2014, 2014, 1-9.	1.1	23
120	Percutaneous closure of postinfarct muscular ventricular septal defects: A multicenter study in China. <i>Journal of Cardiology</i> , 2014, 64, 285-289.	0.8	20
121	Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: A case report. <i>Oncology Letters</i> , 2014, 8, 886-890.	0.8	4